Philip D Ankeny Net Worth

The estimated Net Worth of Philip D Ankeny is at least $1.41 Milion dollars as of 6 October 2009. Philip Ankeny owns over 5,000 units of Surmodics stock worth over $1,264,304 and over the last 21 years Philip sold SRDX stock worth over $148,750.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Philip Ankeny SRDX stock SEC Form 4 insiders trading

Philip has made over 1 trades of the Surmodics stock since 2009, according to the Form 4 filled with the SEC. Most recently Philip sold 5,000 units of SRDX stock worth $148,750 on 6 October 2009.

The largest trade Philip's ever made was selling 5,000 units of Surmodics stock on 6 October 2009 worth over $148,750. On average, Philip trades about 357 units every 0 days since 2004. As of 6 October 2009 Philip still owns at least 32,228 units of Surmodics stock.

You can see the complete history of Philip Ankeny stock trades at the bottom of the page.

What's Philip Ankeny's mailing address?

Philip's mailing address filed with the SEC is 353 FERNDALE ROAD SOUTH, , WAYZATA, MN, 55391.

Insiders trading at Surmodics

Over the last 21 years, insiders at Surmodics have traded over $26,204,565 worth of Surmodics stock and bought 19,725 units worth $436,251 . The most active insiders traders include Jeffrey C Smith, Gary R Maharaj a Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of $415,014. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth $706,662.

What does Surmodics do?

surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.

Complete history of Philip Ankeny stock trades at Surmodics

Surmodics executives and stock owners

Surmodics executives and other stock owners filed with the SEC include:

• Gary Maharaj,
  President, Chief Executive Officer, Director
• Gary R. Maharaj,
  CEO, Pres & Director
• Teri Sides,
  Senior Vice President, Chief Marketing Officer
• Charles Olson,
  Senior Vice President of Commercial and Business Development, Medical Devices
• Gregg Sutton,
  Vice President - Research and Development, Medical Devices
• Thomas Greaney,
  Chief Operating Officer, Medical Devices
• Timothy Arens,
  Chief Financial Officer, Vice President - Finance
• Joseph Stich,
  Vice President, General Manager - In Vitro Diagnostics
• Gordon S. Weber,
  Sr. VP of Legal, Gen. Counsel & Sec.
• Timothy J. Arens,
  Sr. VP of Fin. & Information Technology and CFO
• Joseph J. Stich,
  Sr. VP and GM of HR & In Vitro Diagnostics
• Teryl L. W. Sides,
  Sr. VP of Product Devel. & Chief Marketing Officer
• Susan Knight,
  Non-Executive Independent Chairman of the Board
• Ronald Kalich,
  Independent Director
• David Dantzker,
  Independent Director
• Jose Bedoya,
  Independent Director
• Shawn McCormick,
  Independent Director
• Lisa Heine,
  Independent Director
• Nusrath Sultana,
  Vice President - Clinical Affairs
• Gordon Weber,
  Senior Vice President - Legal, General Counsel, Secretary
• Gregg S. Sutton,
  VP of R&D - Medical Devices
• Charles W. Olson,
  Sr. VP of Commercial & Bus. Devel. of Medical Devices
• John D. Manders,
  Corp. Controller & Principal Accounting Officer
• Lise W Duran,
  VP Product Development
• Andrew D. C. La Frence,
  VP of Finance & CFO
• Amy E. Seibert,
  Principal Accounting Officer
• Michael J Shoup,
  Vice President
• Douglas P Astry,
  General Manager
• Aron B Anderson,
  VP & Chief Scientific Officer
• John C. Middleton,
  VP, Drug Del, Product Dev
• Brian L Robey,
  Vice President
• Paul A Lopez,
  Vice President
• Bruce Barclay,
  President & COO
• John D. Manders,
  Corporate Controller
• Steven J Keough,
  VP & Chief IP Counsel
• Peter L Ginsberg,
  Vice President
• Bryan K Phillips,
  SVP, Gen Counsel & Secretary
• Kendrick B Melrose,
  Director
• David A Koch,
  Director
• Dale R Olseth,
  Chairman and CEO
• Loren R Miller,
  Vice President and Controller
• David S Wood,
  VP & GM - Drug Del. Bus. Unit
• Patrick E Guire,
  Senior Vice President
• Gregory T Yung,
  VP Sales & Business Developmen
• Ronald F Ofstead,
  VP Chemistry Development
• Richard C Carlson,
  VP of Strategic Planning
• Jane M Nichols,
  Vice President Marketing
• Marie J Versen,
  Vice President
• John W Benson,
  Director
• Mary K Brainerd,
  Director
• Mark A. Lehman,
  Treasurer
• Scott R. Ward,
  Director
• Gerald B Fischer,
  Director
• Timothy S Nelson,
  Director
• Robert C Buhrmaster,
  Director
• Eugene C. Rusch,
  VP, Manufacturing
• Value Lp Starboard Value Gp...,
  
• Philip D Ankeny,
  Chief Financial Officer
• Jeffrey C Smith,
  Director
• John A Meslow,
  Director
• Jan M Webster,
  Vice President, HR
• Arthur J Tipton,
  Vice President
• Kenneth H Keller,
  Director